These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34767372)

  • 1. A Duplex CRISPR-Cas9 Ribonucleoprotein Nanomedicine for Colorectal Cancer Gene Therapy.
    Wan T; Pan Q; Liu C; Guo J; Li B; Yan X; Cheng Y; Ping Y
    Nano Lett; 2021 Nov; 21(22):9761-9771. PubMed ID: 34767372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
    Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
    J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
    Lee SK; Hwang JH; Choi KY
    Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
    Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
    Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway.
    Jeong WJ; Ro EJ; Choi KY
    NPJ Precis Oncol; 2018; 2(1):5. PubMed ID: 29872723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease.
    Lin S; Han S; Wang X; Wang X; Shi X; He Z; Sun M; Sun J
    ACS Nano; 2024 Sep; 18(37):25657-25670. PubMed ID: 39215751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential Therapeutic Applications of CRISPR/Cas9 in Colorectal Cancer.
    Sahranavard T; Mehrabadi S; Pourali G; Maftooh M; Akbarzade H; Hassanian SM; Mobarhan MG; Ferns GA; Khazaei M; Avan A
    Curr Med Chem; 2024; 31(35):5768-5778. PubMed ID: 37724673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editing the immune system in vivo in mice using CRISPR/Cas9 ribonucleoprotein (RNP)-mediated gene editing of transplanted hematopoietic stem cells.
    Wang R; Graham S; Gao L; Tam J; Levesque MC
    Methods; 2021 Oct; 194():30-36. PubMed ID: 33422676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenomatous Polyposis Coli as a Major Regulator of Human Embryonic Stem Cells Self-Renewal.
    Preisler L; Ben-Yosef D; Mayshar Y
    Stem Cells; 2019 Dec; 37(12):1505-1515. PubMed ID: 31461190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9: a powerful tool in colorectal cancer research.
    Hu Y; Liu L; Jiang Q; Fang W; Chen Y; Hong Y; Zhai X
    J Exp Clin Cancer Res; 2023 Nov; 42(1):308. PubMed ID: 37993945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy.
    Ruan W; Jiao M; Xu S; Ismail M; Xie X; An Y; Guo H; Qian R; Shi B; Zheng M
    J Control Release; 2022 Nov; 351():739-751. PubMed ID: 36174804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes.
    Takeda H; Kataoka S; Nakayama M; Ali MAE; Oshima H; Yamamoto D; Park JW; Takegami Y; An T; Jenkins NA; Copeland NG; Oshima M
    Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15635-15644. PubMed ID: 31300537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
    Zhan T; Ambrosi G; Wandmacher AM; Rauscher B; Betge J; Rindtorff N; Häussler RS; Hinsenkamp I; Bamberg L; Hessling B; Müller-Decker K; Erdmann G; Burgermeister E; Ebert MP; Boutros M
    Nat Commun; 2019 May; 10(1):2197. PubMed ID: 31097693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination.
    Novellasdemunt L; Foglizzo V; Cuadrado L; Antas P; Kucharska A; Encheva V; Snijders AP; Li VSW
    Cell Rep; 2017 Oct; 21(3):612-627. PubMed ID: 29045831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer.
    Zhang Y; Guo L; Li Y; Feng GH; Teng F; Li W; Zhou Q
    Mol Cancer; 2018 Jan; 17(1):1. PubMed ID: 29304823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
    Li S; Song Z; Liu C; Chen XL; Han H
    ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.